Matches in Nanopublications for { ?s ?p "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.
- assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP498849.RActjo-JT5FVKsfzfRA2Mvpxr_OdfZPcb5PavPIdrD50M130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP498849.RActjo-JT5FVKsfzfRA2Mvpxr_OdfZPcb5PavPIdrD50M130_provenance.
- NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420285.RAqJw3Z-C0sVq2P5NDR7enJYHmpR1IBdIluUUEoDGvacc130_provenance.
- NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420448.RAPt0qQBq4VhyypO6VaGTr_WqUWS71-Sxu3w81jt5GvUU130_provenance.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.